MPM BioImpact’s Rapport Therapeutics RAPP Stock Holding History

MPM BioImpact’s Portfolio RAPP Stock Details RAPP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-71,807	Closed	-$2.13M	–	55
2025 Q3	$2.13M	Buy	+71,807	New	+$1.28M	0.35%	38

Other funds holding RAPP

TGV

TRV GP V Boston, Massachusetts $498M AUM 267.53% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

AVM

Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return

MPM BioImpact's RAPP Position: Q4 2025 in Review

MPM BioImpact sold out of Rapport Therapeutics (RAPP) in Q4 2025, closing a stake of 71,807 shares — an estimated $2.13M sold.

MPM BioImpact first reported a position in RAPP in Q3 2025 and held it in 1 quarter. The position peaked at $2.13M in Q3 2025. 144 funds tracked by Wall St. Rank hold RAPP as of Q4 2025.

MPM BioImpact reported no remaining Rapport Therapeutics position as of Q4 2025 after selling out during the quarter.
MPM BioImpact sold 71,807 Rapport Therapeutics shares in Q4 2025, an estimated $2.13M.
MPM BioImpact first reported a position in Rapport Therapeutics in Q3 2025 and held it in 1 quarter.
MPM BioImpact's Rapport Therapeutics position peaked at $2.13M in Q3 2025.
144 funds tracked by Wall St. Rank held Rapport Therapeutics as of Q4 2025.

Based on MPM BioImpact's 13F filing for Q4 2025, filed 17 Feb 2026.